Loading...

CYTM

GDTC

CYTOMED THERAPEUTICS LTD

(GDTC)

2025 6-K

Share Purchase Agreement

15 May '26

Name Change

11 May '26

Annual Meeting Notice

14 Apr '26

Financial Results Report

31 Mar '26

Regulatory Clarification

28 Jan '26

Shareholder Update

13 Jan '26

Clinical Trial Partnership

8 Dec '25

Asset Acquisition

18 Nov '25

Investment Secured

6 Nov '25

Share Purchase Announcement

22 Oct '25

Cash Bid Announcement

14 Oct '25

Research Collaboration

2 Oct '25

Financial Results Report

30 Sep '25

Company Expansion

28 Aug '25

ATM Offering Program

18 Aug '25

Clinical Trial Update

21 Jul '25

Share Issuance Approval

3 Jul '25

Annual Meeting Results

3 Jul '25

Annual Meeting Notice

16 May '25

Financial Results Update

28 Apr '25

Collaboration Agreement

6 Jan '25

Leadership Changes

5 Dec '24

First Patient Dosed

20 Nov '24

Clinical Trial Funding

7 Oct '24

Asset Acquisition

3 Oct '24

Financial Report Update

30 Sep '24

Board Restructure

24 Jun '24

Board Resignation

20 Jun '24

Annual Shareholders Meeting

24 May '24

Proxy Statement Update

25 Apr '24

Annual Meeting Notice

24 Apr '24

Shareholder Cell Banking

18 Mar '24

Research Partnership

4 Mar '24

Patent Granted

29 Jan '24

External Links:

SEC

On December 8, 2025, CytoMed Therapeutics Limited announced a Memorandum of Understanding with Universiti Malaya Medical Centre to explore a Phase I clinical trial for their gamma delta T cell product in cancer patients. This trial aims to test the safety and effectiveness of using gamma delta T cells from healthy donors for patients who have run out of treatment options.

AI Assistant

CYTOMED THERAPEUTICS LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.